Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Stocks Making Headlines Today?

Page 1 of 2

Although crude futures have rallied by over 2% and the Dow Jones is 100 points higher today, shares of Aduro BioTech Inc (NASDAQ:ADRO), Trevena Inc (NASDAQ:TRVN), Zynga Inc (NASDAQ:ZNGA), Charter Communications, Inc. (NASDAQ:CHTR), and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) each opened deep in the red before moving sharply in various directions. Let’s find out why traders were selling these stocks this morning and check out how the world’s greatest investors are positioned in each stock.

Our research, which determined that following the small-cap stocks that hedge funds are collectively bullish on can help a smaller investor to beat the S&P 500 by around 95 basis points per month (see the details here).

Aduro Fails to Achieve Endpoint

Aduro BioTech Inc (NASDAQ:ADRO) is 23% lower today after the biotech announced that its Phase 2b study, ECLIPSE, which was investigating the company’s lead product candidate CRS-207 for the treatment of metastatic pancreatic cancer, showed that the drug failed to achieve the study’s primary endpoint in terms of it prolonging overall survival. The interim results of a second study, STELLAR, which also studies CRS-207, will be available later in 2016. The number of elite funds in our system with holdings in Aduro BioTech Inc (NASDAQ:ADRO) fell by one quarter-over-quarter to eight as of the end of 2015.

Follow Aduro Biotech Inc. (NASDAQ:ADRO)
Trade (NASDAQ:ADRO) Now!

Trevena Ending TRV027 Development

Trevena Inc (NASDAQ:TRVN) has retreated by 7% after the company announced disappointing results from a trial of its own, which showed that TRV027, the company’s candidate for acute heart failure, failed to beat the results of a placebo in Phase 2b clinical trials. As a result, Trevena Inc (NASDAQ:TRVN) will terminate the development of TRV027 and dedicate its efforts towards TRV130 instead, which is a potential treatment for moderate-to-severe pain. Kevin Kotler’s Broadfin C apital was a major shareholder of Trevena at the end of March.

Follow Trevena Inc (NASDAQ:TRVN)
Trade (NASDAQ:TRVN) Now!

On the next page we examine why Zynga Inc, Charter Communications, and Valeant are all on the move today.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!